A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly’s and Novo’s GLP-1 Duopoly

You probably already know that pharmaceutical powerhouses Novo Nordisk (NVO 2.36%) and Eli Lilly (LLY 2.67%) dominate the anti-obesity drug market, and in fact, largely invented the business as we know it today.

Ozempic — Novo’s brand name for…